Life Competence - the first global picture on the EU-funded health research

It is now possible to have a global picture of which research organisations and which research areas were funded by the European Commission during the 2001-2006 years (6th European Research Framework Programme). The data has been generated from an online webbased database of competences, supported through an EU specific support action.

The project has been implemented by AVEDAS AG, Germany, Karolinska Institutet, Sweden and EuropaBio, Belgium. It contains all the health related projects funded by the EU during the last Research Framework Programme, as well as the principal organisations participating in these projects. The aim of this database is to increase transparency and accessibility of research competences in Europe, both for Europeans (in a recent Eurobarometer, 70% of them expressed their interest in health research) but also for other nationalities interested in participating in the European Health Research effort.

In the European Research Programme going from 2001 to 2006 (FP6), the part of the programme focussing on health research was major with its budget of € 2.4 billion supporting 680 projects. It was shared between different research areas with about 50% of the projects and budget dedicated to disease oriented research areas. Cancer is the area receiving most support with 123 projects, about 18 % of projects partly or entirely focussed on cancer, with 22 % of the budget (€ 539 million). Other important research areas are AIDS/HIV, Stem Cell Research, Diabetes, Diagnostics, Vaccines and Drug design.

An important policy in the EU is to support competitiveness by encouraging cooperation of academia and clinicians with industry, and especially with small and medium-sized enterprises (SMEs). Out of 2.438 unique partners in health research projects, 853 are from the private sector, of which 365 SMEs (15%). It means that around 20 % of the total number of SMEs in the Health sector are participating in the EU programme. The majority of partners in the programme are academic.

Another important policy in European research is international cooperation. Participation from countries outside Europe and its associated states represents about 5% of partners of health projects. The highest number of participations are from China, Russia, US and South Africa. Within Europe, about 6% of the partners are from the 12 new EU-member states and 7% of the partners are from the states associated to the EU with science and technology cooperation agreements that involved contributing to the framework programme budget.

It is expected that the 'LifeCompetence' database will have many positive implications for the Health research society in Europe and for worldwide cooperations, e.g. increased knowledge transfer, better partnerships and more efficient management of research programmes and research organisations, as well as providing a transparent information on the resources invested in funding health research at the European level.

For further information, please visit:
http://www.lifecompetence.eu

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...